SCHEMBL426994

SCHEMBL426994

CN(C(=O)n1cnc(-c2ccc(N)cc2)c1)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.51
SMN1; SMN2 Q16637 2/20 0.45
PHGDH O43175 1/20 0.40
KDM4E B2RXH2 2/20 0.39
CES2 O00748 1/20 0.39
PPIB P23284 1/20 0.38
ACHE P22303 2/20 0.38
LIPE Q05469 2/20 0.38
KMT2A Q03164 3/20 0.38
MEN1 O00255 2/20 0.38
ALDH1A1 P00352 2/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
LMNA P02545 2/20 0.38
TP53 P04637 1/20 0.38
LTB4R Q15722 1/20 0.37
ALPL P05186 1/20 0.37
TSHR P16473 1/20 0.37
RAB9A P51151 1/20 0.37
GFER P55789 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL427476 0.91 FAAH (0.57) FAAHSMN1; SMN2KDM4ECES2ACHE
SCHEMBL425371 0.90 FAAH (0.60) FAAHSMN1; SMN2KDM4ECES2ACHE
SCHEMBL426698 0.88 FAAH (0.52) FAAHSMN1; SMN2KDM4ECES2ACHE
SCHEMBL427556 0.87 FAAH (0.49) FAAHSMN1; SMN2PHGDHKDM4EACHE
SCHEMBL425400 0.87 FAAH (0.54) FAAHSMN1; SMN2ACHELIPEALDH1A1
SCHEMBL425550 0.87 FAAH (0.51) FAAHSMN1; SMN2KDM4ECES2KMT2A
SCHEMBL425535 0.85 FAAH (0.49) FAAHSMN1; SMN2KDM4ECES2ACHE
SCHEMBL426694 0.85 ACHE (0.49) FAAHSMN1; SMN2PHGDHKDM4EACHE
SCHEMBL426080 0.82 FAAH (0.52) FAAHSMN1; SMN2KDM4ECES2KMT2A
SCHEMBL425544 0.80 FAAH (0.52) FAAHPHGDHACHELIPEALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-9353082-B2 Pharmaceutical compounds BIAL—PORTELA & CA, S.A. (PT) 2016-05-31 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2012-03-15 US disclosed
WO-2010074588-A2 PHARMACEUTICAL COMPOUNDS BIAL - PORTELA & Cª, S.A. (PT) 2010-07-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120065191-A1 PHARMACEUTICAL COMPOUNDS FAAH, FAAH2, ASAH1 FAAH 1/4885SMN1; SMN2 2818/4885PHGDH 190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.